Last reviewed · How we verify
ZVS101e
ZVS101e is a small molecule that targets the SGLT2 receptor.
ZVS101e is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | ZVS101e |
|---|---|
| Also known as | rAAV2/8-hCYP4V2, rAAV8-hCYP4V2, AAV8-hCYP4V2, AAV2/8-hCYP4V2, Puliretgene parvec |
| Sponsor | Peking University Third Hospital |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, ZVS101e reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Compassionate Administration of ZVS101e Injection for Extended Treatment (NA)
- Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy (PHASE3)
- Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy (PHASE1, PHASE2)
- Safety Study of rAAV2/8-hCYP4V2 in Patients With Bietti's Crystalline Dystrophy (BCD) (EARLY_PHASE1)
- Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZVS101e CI brief — competitive landscape report
- ZVS101e updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI